Literature DB >> 10464623

Cystic fibrosis in Jews: frequency and mutation distribution.

B Kerem1, O Chiba-Falek, E Kerem.   

Abstract

The incidence of cystic fibrosis and the frequency of disease causing mutations varies among different ethnic groups and geographical regions around the world. The Jewish population is comprised of two major ethnic groups. Ashkenazi and Non-Ashkenazi. The latter is further classified according to country of origin. An extreme variability in the disease frequency (from 1:2400-1:39,000) was found among the different Jewish ethnic groups. In the entire Jewish CF population, only 12 mutations were identified that altogether enable the identification of 91% of the CF chromosomes. However, in each Jewish ethnic group, the disease is caused by a different repertoire of a small number of mutations. In several ethnic groups, there is a major CFTR mutation that accounts for at least 48% of the CF chromosomes. High proportion of the CF chromosomes can be identified in Ashkenazi Jews (95%), Jews originating from Tunisia (100%), Libya (91%), Turkey (90%), and Georgia (88%). High frequencies of CFTR mutations were found among infertile males with CBAVD who might not have additional CF clinical characteristics. Of the Jewish males with CBAVD, 77% carried at least one CFTR mutation. The 5T mutation is the major mutation in Jewish CBAVD affecteds accounting for 32% of the chromosomes among Ashkenazi Jews and 36% among the non-Ashkenazi Jews. Five additional CFTR mutations, W1282X (12%), delta F508 (9%), N1303K (3%), D1152H, (5%)), and R117H (1%) were identified among Ashkenazi Jews with CBAVD. Only two mutations, delta F508 and R117H, were found among non-Ashkenazi males with CBAVD. An increased frequency of the 5T allele was also found among Jewish patients with atypical CF presentation, 18% in Ashkenazi, and 10% in non-Ashkenazi Jews. In summary, we present the required information for genetic counseling of Jewish families with typical and atypical CF and for carrier screening of healthy Jewish individuals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10464623     DOI: 10.1089/gte.1997.1.35

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  17 in total

1.  Replication strategies for rare variant complex trait association studies via next-generation sequencing.

Authors:  Dajiang J Liu; Suzanne M Leal
Journal:  Am J Hum Genet       Date:  2010-12-10       Impact factor: 11.025

2.  Clinical, genetic, and electrophysiologic characteristics of a new PAS-domain HERG mutation (M124R) causing Long QT syndrome.

Authors:  Liat Shushi; Batsheva Kerem; Maya Goldmit; Asher Peretz; Bernard Attali; Aron Medina; Jeffrey A Towbin; Junko Kurokawa; Robert S Kass; Jesaia Benhorin
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-07       Impact factor: 1.468

3.  Cystic Fibrosis: The Dawn of a New Therapeutic Era.

Authors:  Sonya L Heltshe; Jonathan Cogen; Kathleen J Ramos; Christopher H Goss
Journal:  Am J Respir Crit Care Med       Date:  2017-04-15       Impact factor: 21.405

4.  Multiple forms of casein kinase from rabbit erythrocytes.

Authors:  R Kumar; M Tao
Journal:  Biochim Biophys Acta       Date:  1975-11-20

Review 5.  Cystic fibrosis therapeutics: the road ahead.

Authors:  Lucas R Hoffman; Bonnie W Ramsey
Journal:  Chest       Date:  2013-01       Impact factor: 9.410

Review 6.  CFTR: A New Horizon in the Pathomechanism and Treatment of Pancreatitis.

Authors:  Péter Hegyi; Michael Wilschanski; Shmuel Muallem; Gergely L Lukacs; Miklós Sahin-Tóth; Aliye Uc; Michael A Gray; Zoltán Rakonczay; József Maléth
Journal:  Rev Physiol Biochem Pharmacol       Date:  2016       Impact factor: 5.545

7.  Class 1 CF Mutations.

Authors:  Michael Wilschanski
Journal:  Front Pharmacol       Date:  2012-06-20       Impact factor: 5.810

8.  Discovery of rare variants via sequencing: implications for the design of complex trait association studies.

Authors:  Bingshan Li; Suzanne M Leal
Journal:  PLoS Genet       Date:  2009-05-15       Impact factor: 5.917

Review 9.  Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders.

Authors:  Samuel M Moskowitz; James F Chmiel; Darci L Sternen; Edith Cheng; Ronald L Gibson; Susan G Marshall; Garry R Cutting
Journal:  Genet Med       Date:  2008-12       Impact factor: 8.822

10.  Helicobacter pylori and Clostridium difficile in cystic fibrosis patients.

Authors:  Jacob Yahav; Zmira Samra; Hannah Blau; Gabriel Dinari; Gabriel Chodick; Haim Shmuely
Journal:  Dig Dis Sci       Date:  2006-11-01       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.